The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Sometimes the most under-hyped sectors are the best places to build very large businesses,” said one venture investor who ...

Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

After several severe RSV cases were reported in a pediatric trial of Moderna's vaccine, the FDA has partially paused testing ...

The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...